

RealRate

PHARMACEUTICAL 2022

Cogent Biosciences Inc. Rank 95 of 466









RealRate



Cogent Biosciences Inc. Rank 95 of 466

The relative strengths and weaknesses of Cogent Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cogent Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 66% points. The greatest weakness of Cogent Biosciences Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 237%, being 159% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	222,633
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	17,077
Liabilities, Non-Current	831
Other Assets	7,753
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	3,278
Other Revenues	0
Property and Equipment	1,706
Research and Development	55,913
Selling, General and Administrative Expense	19,638

Output Variable	Value in 1000 USD
Assets	232,092
Liabilities	17,908
Expenses	75,551
Revenues	0
Stockholders Equity	214,184
Net Income	-72,273
Comprehensive Net Income	-72,273
Economic Capital Ratio	237%

